DRUG PROFILE Anidulafungin: a novel echinocandin
نویسندگان
چکیده
971 (2003). 71. Reboli A, Rotstein C, Pappas P, Schranz J, Krause D, Walsh T. Anidulafungin vs fluconazole for treatment of candidemia andinvasive candidiaisis. Presented at: The 45thInterscience Conference on AntimicrobialAgents and Chemotherapy, December 15–19, DC, USA. Abstract 1040, (2005). 72. Schranz J, Krause D, Henkel T. Lack ofinfusion-related adverse events withanidulafungin. Presented at: The 15thCongress of the International Society forHuman and Animal Mycology, May 25–29, TX, USA. Abstract 399 (2003).73. Thye D, Shepherd B, White RJ et al. Anidulafungin: a Phase 1 study to identify the maximum tolerated dose in healthyvolunteers. Presented at: The 41stInterscience Conference on AntimicrobialAgents and Chemotherapy, December 16–19, IL, USA. Abstract 36 (2001). 74. Krause D, Schranz J, Birmingham W. Safety results from a Phase 3, randomized, double-blind, double-dummy study of anidulafungin (ANID) vs fluconazole (FLU) in patients with esophageal candidiasis (EC).Presented at: The 41st Interscience Conferenceon Antimicrobial Agents and Chemotherapy,December 16–19, IL, USA Abstract 136
منابع مشابه
Structure-Activity Relationships of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble Echinocandin with Distinctive Pharmacokinetic Properties
Echinocandins are a first-line therapy for candidemia and invasive candidiasis. They are generally safe with few drug interactions, but the stability and pharmacokinetic properties of currently approved echinocandins are such that each was developed for daily intravenous infusion. We sought to discover a novel echinocandin with properties that would enable more flexible dosing regimens, alterna...
متن کاملAnidulafungin: a new addition to the antifungal armamentarium
10.2217/14750708.4.2.125 © 2 Invasive fungal infections continue to be associated with high rates of morbidity and mortality, primarily in the immunocompromised hosts. Candida and Aspergillus are the most common causes of invasive fungal disease; however, other fungi can also cause disease in humans. Current therapeutic options for the management of invasive fungal infections include the polyen...
متن کاملSerum differentially alters the antifungal properties of echinocandin drugs.
Antifungal efficacies of the echinocandin drugs caspofungin, micafungin, and anidulafungin were reduced significantly in the presence of 50% human serum, which yielded nearly equivalent MICs or minimum effective concentrations against diverse Candida spp. and Aspergillus spp. Consistent with a direct drug interaction, serum decreased the sensitivity of glucan synthase to echinocandin drugs.
متن کاملCD101: a novel long‐acting echinocandin
CD101 is a novel echinocandin drug being developed to treat severe fungal infections including invasive candidiasis. We have performed a series of studies to evaluate the antifungal properties of CD101 against both echinocandin-susceptible and -resistant Candida strains. Antifungal susceptibility testing performed on a collection of 95 Candida strains including 30 caspofungin-resistant isolates...
متن کاملCharacterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species
CD101 is a novel echinocandin with a long half-life undergoing clinical development for treatment of candidemia/invasive candidiasis and vulvovaginal candidiasis. The potential for and mechanisms underlying the development of resistance to CD101 in Candida species were investigated by using spontaneous resistance and serial passage selection methodologies. Four Candida spp. (C. albicans, C. gla...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2003